Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2005

01-06-2005 | Article

Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats

Authors: D. M. Ouwens, C. Boer, M. Fodor, P. de Galan, R. J. Heine, J. A. Maassen, M. Diamant

Published in: Diabetologia | Issue 6/2005

Login to get access

Abstract

Aims/hypothesis

Diabetic cardiomyopathy (DCM) is common in type 2 diabetes. In DCM, insulin resistance may alter cardiac substrate supply and utilisation leading to changes in myocardial metabolism and cardiac function. In rats, exposure to excessive alimentary fat, inducing a type 2 diabetic phenotype, may result in myocardial insulin resistance and cardiac functional changes resembling DCM.

Materials and methods

Rats received high-fat (HFD) or low-fat (LFD) diets for 7 weeks. Prior to killing, insulin or saline was injected i.p. Contractile function and insulin signalling were assessed in papillary muscles and ventricular lysates, respectively.

Results

Fasting and post-load blood glucose levels were increased in HFD- vs LFD-rats (all p<0.02). Mean heart weight, but not body weight, was increased in HFD-rats (p<0.01). HFD-hearts showed structural changes and triglyceride accumulation. HFD-muscles developed higher baseline and maximum forces, but showed impaired recovery from higher workloads. Insulin-associated modulation of Ca2+-induced force augmentation was abolished in HFD-muscles. HFD reduced insulin-stimulated IRS1-associated phosphatidylinositol 3′-kinase activity and phosphorylation of protein kinase B, glycogen synthase kinase-3β, endothelial nitric oxide synthase, and forkhead transcription factors by 40–60% (all p<0.05). Insulin-mediated phosphorylation of phospholamban, a critical regulator of myocardial contractility, was decreased in HFD-hearts (p<0.05).

Conclusions/interpretation

HFD induced a hypertrophy-like cardiac phenotype, characterised by a higher basal contractile force, an impaired recovery from increased workloads and decreased insulin-mediated protection against Ca2+ overload. Cardiac dysfunction was associated with myocardial insulin resistance and phospholamban hypophosphorylation. Our data suggest that myocardial insulin resistance, resulting from exposure to excessive alimentary fat, may contribute to the pathogenesis of diabetes-related heart disease.
Literature
1.
Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34CrossRefPubMed
2.
Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMed
3.
Vanninen E, Mustonen J, Vainio P, Lansimies E, Uusitupa M (1992) Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol 70:371–378CrossRefPubMed
4.
Diamant M, Lamb HJ, Groeneveld Y et al (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328–335CrossRefPubMed
5.
Bell DS (1995) Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18:708–714PubMed
6.
Taegtmeyer H, McNulty P, Young ME (2002) Adaptation and maladaptation of the heart in diabetes: part I. General concepts. Circulation 105:1727–1733CrossRefPubMed
7.
8.
Zhou YT, Grayburn P, Karim A et al (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784–1789CrossRefPubMed
9.
Kessler A, Uphues I, Ouwens DM, Till M, Eckel J (2001) Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase. Am J Physiol Endocrinol Metab 280:E65–E74PubMed
10.
Lamberts RR, Van Rijen MH, Sipkema P, Fransen P, Sys SU, Westerhof N (2002) Coronary perfusion and muscle lengthening increase cardiac contraction: different stretch-triggered mechanisms. Am J Physiol Heart Circ Physiol 283:H1515–H1522PubMed
11.
Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Med Sci 37:911–917
12.
Withers DJ, Ouwens DM, Nave BT et al (1997) Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. Biochem Biophys Res Commun 241:704–709CrossRefPubMed
13.
Christoffersen C, Bollano E, Lindegaard MLS et al (2003) Cardiac lipid accumulation associated with diasystolic dysfunction in obese mice. Endocrinology 144:3483–3490CrossRefPubMed
14.
Perseghin G, Petersen K, Shulman GI (2003) Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 27(Suppl 3):S6–S11CrossRefPubMed
15.
16.
Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109:1580–1589CrossRefPubMed
17.
Belke DD, Betuing S, Tuttle MJ et al (2002) Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109:629–639CrossRefPubMed
18.
Murphy S, Frishman WH (2005) Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol Rev 13:3–12PubMed
19.
Fitzgerald SM, Henegar JR, Brands MW, Henegar LK, Hall JE (2001) Cardiovascular and renal responses to a high-fat diet in Osborne–Mendel rats. Am J Physiol Regul Integr Comp Physiol 281:R547–R552PubMed
20.
Korvald C, Elvenes OP, Myrmel T (2000) Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 278:H1345–H1351PubMed
21.
Borst P, Loos JA, Christ EJ, Slater EC (1962) Uncoupling activity of long-chain fatty acids. Biochim Biophys Acta 62:509–518CrossRefPubMed
22.
Myrmel T, Forsdahl K, Larsen TS (1992) Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol 24:855–868CrossRefPubMed
23.
Philipson KD, Ward R (1985) Effects of fatty acids on Na+–Ca2+ exchange and Ca2+ permeability of cardiac sarcolemmal vesicles. J Biol Chem 260:9666–9671PubMed
24.
Huang JM, Xian H, Bacaner M (1992) Long-chain fatty acids activate calcium channels in ventricular myocytes. Proc Natl Acad Sci U S A 89:6452–6456PubMed
25.
Chiu HC, Kovacs A, Ford DA et al (2001) A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107:813–822PubMed
26.
Finck BN, Lehman JJ, Leone TC et al (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121–130CrossRefPubMed
27.
Young ME, Guthrie PH, Razeghi P et al (2002) Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51:2587–2595PubMed
28.
Abel ED, Kaulbach HC, Tian R et al (1999) Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104:1703–1714PubMed
29.
Atkinson LL, Kozak R, Kelly SE, Onay BA, Russell JC, Lopaschuk GD (2003) Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab 284:E923–E930PubMed
30.
Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE (2003) Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285:H1261–H1269PubMed
31.
Dutta K, Podolin DA, Davidson MB, Davidoff AJ (2001) Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50:1186–1192PubMed
32.
Fath-Ordoubadi F, Beatt KJ (1997) Glucose–insulin–potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96:1152–1156PubMed
33.
Ren J, Walsh MF, Hamaty M, Sowers JR, Brown RA (1999) Augmentation of the inotropic response to insulin in diabetic rat hearts. Life Sci 65:369–380CrossRefPubMed
34.
Ren J, Sowers JR, Walsh MF, Brown RA (2000) Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol 279:H1708–H1714PubMed
35.
Allard MF, Wambolt RB, Longnus SL et al (2000) Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am J Physiol Endocrinol Metab 279:E487–E493PubMed
36.
Doenst T, Goodwin GW, Cedars AM, Wang M, Stepkowski S, Taegtmeyer H (2001) Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vitro. Metabolism 50:1083–1090CrossRefPubMed
37.
Sasso FC, Carbonara O, Cozzolino D et al (2000) Effects of insulin–glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients: a radionuclide ventriculographic study. J Am Coll Cardiol 36:219–226CrossRefPubMed
38.
Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS (2001) Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 50:2133–2138PubMed
39.
Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR (1997) Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart. J Biol Chem 272:23696–23702CrossRefPubMed
40.
Dutta K, Carmody MW, Cala SE, Davidoff AJ (2002) Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy. J Mol Cell Cardiol 34:985–996CrossRefPubMed
41.
Belke DD, Swanson EA, Dillmann WH (2004) Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53:3201–3208PubMed
42.
MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4:566–577CrossRefPubMed
43.
Zierath JR, Krook A, Wallberg-Henriksson H (2000) Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821–835CrossRefPubMed
44.
Youngren JF, Paik J, Barnard RJ (2001) Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin-resistant rats. J Appl Physiol 91:2240–2247PubMed
45.
Mazumder PK, O’Neill BT, Roberts MW et al (2004) Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53:2366–2374PubMed
46.
Carvalheira JB, Calegari VC, Zecchin HG et al (2003) The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 144:5604–5614CrossRefPubMed
47.
Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C (2001) A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50:2210–2218PubMed
48.
Gergs U, Boknik P, Buchwalow I et al (2004) Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem 279:40827–40834CrossRefPubMed
49.
Gao F, Gao E, Yue TL et al (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497–1502CrossRefPubMed
50.
Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421–426CrossRefPubMed
Metadata
Title
Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats
Authors
D. M. Ouwens
C. Boer
M. Fodor
P. de Galan
R. J. Heine
J. A. Maassen
M. Diamant
Publication date
01-06-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1755-x

Other articles of this Issue 6/2005

Diabetologia 6/2005 Go to the issue

Article

Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats

Article

Hyperinsulinaemia triggered by dietary conjugated linoleic acid is associated with a decrease in leptin and adiponectin plasma levels and pancreatic beta cell hyperplasia in the mouse

Short Communication

Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males

Review

An immune origin of type 2 diabetes?

Article

Dysregulation of energy homeostasis in mice overexpressing insulin-like growth factor-binding protein 6 in the brain

Article

Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits